ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Distribution, antibacterial resistance, biofilm formation, and risk factors associated with carbapenemase-producing gram-negative bacteria in ICU patients.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gram-negative bacteria are major contributors to intensive care unit (ICU)-acquired infections, further complicated by biofilm formation, multidrug resistance (MDR), and carbapenemase production. This study, conducted in Uttar Pradesh, India (2022-2023), assessed the distribution, antibacterial resistance profiles, biofilm formation, and risk factors associated with carbapenemase-producing organisms (CPOs) in ICU patients. A total of 321 g-negative bacteria (GNB) isolates were recovered from 311 clinical samples. Bacterial identification, antibacterial susceptibility testing, biofilm detection, and PCR-based carbapenemase gene analysis were performed. Clinical and demographic variables were evaluated to determine factors associated with CPO infections and outcomes. The predominant pathogens were Pseudomonas aeruginosa 109 (34%), Klebsiella pneumoniae 77 (24%), and Escherichia coli 53 (16.5%). High resistance rates were observed for β-lactams and fluoroquinolones, whereas carbapenems, aminoglycosides, and polymyxins remained largely effective. Biofilm formation was noted in Acinetobacter baumannii 23 (74.2%), K. pneumoniae 56 (72.7%), P. aeruginosa 74 (67.9%), and E. coli 34 (64.1%). The most prevalent carbapenemase genes were blaNDM-1 28 (45.9%), blaOXA-48 14 (23%), and blaVIM 7 (11.5%), with co-existence in 13 isolates (21.3%). CPO infections occurred in 61/311 patients (19.6%). Significant risk factors included male sex (42; 68.9%), age > 40 years (43; 70.5%), ICU stay > 7 days (46; 75.4%), urinary catheterization (41; 67.2%), venous catheterization (37; 60.7%), and mechanical ventilation (40; 65.6%). Mortality was higher in CPO-infected patients (23; 37.7%) than in non-CPO cases (52; 20.8%). Biofilm formation and carbapenemase genes are key drivers of MDR-GNB in ICUs. CPO infections are strongly linked to invasive device use and increased mortality, underscoring the need for robust antibacterial stewardship and infection control practices.
Indexed as
Identifiers
41879843What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.